IL313728A - Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders - Google Patents
Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disordersInfo
- Publication number
- IL313728A IL313728A IL313728A IL31372824A IL313728A IL 313728 A IL313728 A IL 313728A IL 313728 A IL313728 A IL 313728A IL 31372824 A IL31372824 A IL 31372824A IL 313728 A IL313728 A IL 313728A
- Authority
- IL
- Israel
- Prior art keywords
- saponin
- bond
- xyl
- rha
- fuc
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Botany (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2030215 | 2021-12-22 | ||
| PCT/NL2022/050736 WO2023121446A1 (en) | 2021-12-22 | 2022-12-20 | Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL313728A true IL313728A (en) | 2024-08-01 |
Family
ID=81585344
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL313728A IL313728A (en) | 2021-12-22 | 2022-12-20 | Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250057971A1 (https=) |
| EP (2) | EP4452331B8 (https=) |
| JP (1) | JP2025500482A (https=) |
| KR (1) | KR20240121778A (https=) |
| CN (1) | CN118414172A (https=) |
| CA (1) | CA3240612A1 (https=) |
| DK (1) | DK4452331T3 (https=) |
| ES (1) | ES3052234T3 (https=) |
| IL (1) | IL313728A (https=) |
| PT (1) | PT4452331T (https=) |
| WO (1) | WO2023121446A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202100928QA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| CA3108282A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| KR20260025101A (ko) * | 2023-06-02 | 2026-02-23 | 사프렘 테크놀로지스 비.브이. | 세포내 분자 표적을 통해 작용하는 치료적 이펙터 성분을 위한 개선된 치료 요법 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
| US10626395B2 (en) | 2016-10-27 | 2020-04-21 | The General Hospital Corporation | Therapeutic targeting of a microRNA to treat Duchenne muscular dystrophy |
| MX2019008199A (es) | 2017-01-06 | 2019-11-25 | Avidity Biosciences Llc | Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon. |
| IL280536B2 (en) | 2018-08-02 | 2024-12-01 | Dyne Therapeutics Inc | Complexes targeting transferrin receptor and uses thereof |
| SG11202106603UA (en) | 2018-12-21 | 2021-07-29 | Sapreme Tech Bv | Biologically active cluster of molecules |
| CA3163283A1 (en) | 2020-01-10 | 2021-07-15 | Romesh R. Subramanian | Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health |
-
2022
- 2022-12-20 US US18/723,157 patent/US20250057971A1/en active Pending
- 2022-12-20 PT PT228306213T patent/PT4452331T/pt unknown
- 2022-12-20 CN CN202280083977.7A patent/CN118414172A/zh active Pending
- 2022-12-20 DK DK22830621.3T patent/DK4452331T3/da active
- 2022-12-20 ES ES22830621T patent/ES3052234T3/es active Active
- 2022-12-20 WO PCT/NL2022/050736 patent/WO2023121446A1/en not_active Ceased
- 2022-12-20 CA CA3240612A patent/CA3240612A1/en active Pending
- 2022-12-20 KR KR1020247021690A patent/KR20240121778A/ko active Pending
- 2022-12-20 EP EP22830621.3A patent/EP4452331B8/en active Active
- 2022-12-20 JP JP2024538258A patent/JP2025500482A/ja active Pending
- 2022-12-20 IL IL313728A patent/IL313728A/en unknown
- 2022-12-20 EP EP25186753.7A patent/EP4610278A3/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250057971A1 (en) | 2025-02-20 |
| WO2023121446A1 (en) | 2023-06-29 |
| EP4610278A2 (en) | 2025-09-03 |
| PT4452331T (pt) | 2025-10-28 |
| JP2025500482A (ja) | 2025-01-09 |
| DK4452331T3 (da) | 2025-09-29 |
| ES3052234T3 (en) | 2026-01-02 |
| EP4610278A3 (en) | 2025-12-10 |
| CN118414172A (zh) | 2024-07-30 |
| EP4452331A1 (en) | 2024-10-30 |
| EP4452331B1 (en) | 2025-08-06 |
| EP4452331B8 (en) | 2025-09-17 |
| KR20240121778A (ko) | 2024-08-09 |
| CA3240612A1 (en) | 2023-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4452331B1 (en) | Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders | |
| US20250250564A2 (en) | Compositions comprising therapeutic nucleic acid and saponin for the treatment of muscle-wasting disorders | |
| US20250082759A1 (en) | Compositions comprising therapeutic nucleic acid and targeted saponin for the treatment of muscle-wasting disorders | |
| US20230330562A1 (en) | Methods of preparing protein-oligonucleotide complexes | |
| EP4731257A1 (en) | Conjugates of saponin and antisense oligonucleotides for use in the treatment of neurodegenerative diseases | |
| KR20230043111A (ko) | Vhh를 포함하는 adc 또는 aoc, 및 사포닌 또는 리간드-사포닌 접합체를 포함하는 조합물 | |
| HK40129943A (en) | Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders | |
| HK40118872A (en) | Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders | |
| HK40118872B (en) | Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders | |
| US20250295800A1 (en) | Conjugate of a single domain antibody, a saponin and an effector molecule, pharmaceutical composition comprising the same, therapeutic use of said pharmaceutical composition | |
| CN116322783A (zh) | 单结构域抗体、皂苷和效应分子的缀合物，包含其的药物组合物，所述药物组合物的治疗用途 | |
| EP4331609A1 (en) | Methods and compositions for enhanced polyplex delivery | |
| KR20260026556A (ko) | 중추신경계 장애의 치료를 위한 약제학적 조성물 | |
| WO2026087678A1 (en) | Treatment for renal disorders | |
| CN121816200A (zh) | 经由细胞内分子靶标起作用的治疗性效应子组分的改善的治疗方案 | |
| WO2026087680A1 (en) | Treatment for cardiovascular disease | |
| WO2026087695A1 (en) | Treatment for metabolic disorder |